Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Infanrix-hexa + Twinrix-Junior
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This is a combination of two vaccines: 1. **Infanrix-hexa**: A combined vaccine containing diphtheria toxoid, tetanus toxoid, acellular pertussis antigens (pertussis toxoid, filamentous haemagglutinin, and pertactin), hepatitis B virus surface antigen recombinant, inactivated poliovirus types 1, 2 and 3, and Haemophilus influenzae type b polysaccharide conjugated to tetanus toxoid. 2. **Twinrix Junior**: A combined vaccine containing inactivated hepatitis A virus and recombinant hepatitis B surface antigen. It contains half the adult dose of hepatitis B antigen (10 μg) compared to the regular Twinrix. These vaccines are administered separately to provide protection against multiple diseases.
- Brand names
- Infanrix-hexa + Twinrix-Junior
Beyond the preview
Go deeper on Infanrix-hexa + Twinrix-Junior.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Infanrix-hexa + Twinrix-Junior.